Read the GLP-1 research in context, from the study population and comparison to outcomes, limitations and follow-up.
Semaglutide is the active substance in Wegovy, a prescription medicine for weight management in defined patient groups. It mimics the action of GLP-1 and influences appetite, among other effects. The medicine is used alongside changes in diet and physical activity. The official product information defines the relevant uses and restrictions. A summary of the mechanism is useful background, but an assessment of a treatment needs the clinical evidence and the complete product information as well.
STEP 1 studied adults with overweight or obesity who did not have diabetes. Semaglutide with lifestyle support produced greater weight loss than placebo with lifestyle support. The population, comparison and accompanying support are important parts of that result. A study average is not an individual prediction. When reading a summary, keep the trial’s question intact instead of turning the result into a promise about every person who might encounter the same active ingredient.
Preparing the full guide…
The extended sections are available during your one-minute preview and with free email registration.
- The comparison includes more than a molecule
- Put percentages back into context
- Read unwanted effects with the benefits
- Why product information still matters
- Prepare a discussion about the whole treatment
- A proportionate conclusion
Sources & further reading
Sources support specific statements, not every possible use of a molecule. Echo hub articles provide research background; original publications and official guidance are identified where supplied.
- EMA — Wegovy
- STEP 1 — Once-Weekly Semaglutide in Adults with Overweight or Obesity
- Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (2023)